The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
Hannah Goulart, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a retrospective study investigating hematological parameters in essential thrombocythemia (ET). The study found no parameters associated with thrombotic risk but found that a lower platelet count correlated with an increased risk of developing post-ET blast-phase or myelofibrosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
